Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Privi Speciality Chemicals Limited (PRIVISCL.NS)
Mumbai, IN
Privi Speciality Chemicals Limited is a global manufacturer, supplier, and exporter of a diverse range of aroma and fragrance compounds, with operations extending internationally from its base in India. Its extensive product portfolio encompasses various aroma and fragrance ingredients such as amber fleur, acetates, dihydromyrcenol, ionones, nitriles, and sandalwood derivatives, alongside other specialty and bulk aroma chemicals. The company also produces nutraceutical items. A comprehensive list of its aroma chemical offerings includes alpha damascone, alpha ionone, alpha terpenyl acetate, amber fleur, amber gamma, beta iso damascol, various grades of BI, carene-60 & Carene-90, cedar ketol, citronellal, citronellyl acetate, citronellyl nitrile, dipentene, double distilled turpentine oil, dihydro myrcenol, dihydromyrcene, gamma methyl ionone, gamma terpenyl acetate, geraniol, geranyl acetate, Indian sandal core, ionone, iso boronyl acetate, l-limonene, methyl ionone, nerol, neryl acetate, nimberol, OTBCHA, pine oil, prionyl, PTBCHA, several terpeniol grades (alpha, gamma, MU &BP), terpinolene, sandal fleur, sandal touch, tetrahydroflorol, tetrahydrogeraniol, tetrahydrogeranyl acetate, tetrahydromyrcenol, timber forte, and timber touch. Established in 1985, the company was formerly known as Fairchem Speciality Limited before rebranding to Privi Speciality Chemicals Limited in October 2020, with its headquarters situated in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.81% | -9.74% | +8.10% | +15.88% | -2.39% | +13.14% | +43.46% | +182.67% | +202.69% | +1,038.22% | +993.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+22.6% ★ Q1'26: +19.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+75.2% ★ Q1'26: +40.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+11.2% ★ Q1'26: +11.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+19.6% ★ Q1'26: +19.9% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+20.6% ★ Q1'26: +23.7% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.88× Q1'26: 0.77× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 2 EPS Ana. |
Mar 2028 1 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.50B
est: 1.75B (-14.4%)
|
1.50B
est: 2.83B (-47.1%)
|
5.90B
est: 3.40B (+73.8%)
|
10.13B
est: 9.68B (+4.6%)
|
13.25B
est: 13.16B (+0.8%)
|
13.04B
est: 16.36B (-20.3%)
|
12.68B
est: 18.98B (-33.2%)
|
14.02B
est: 14.45B (-2.9%)
|
16.05B
est: 18.57B (-13.5%)
|
17.52B
est: 24.28B (-27.8%)
|
20.92B
est: 19.67B (+6.3%)
|
25.38B
25.12B – 25.63B
+29.0% YoY
|
31.27B
31.27B – 31.27B
+23.2% YoY
|
40.93B
40.93B – 40.93B
+30.9% YoY
|
42.49B
42.49B – 42.49B
+3.8% YoY
|
50.14B
50.14B – 50.14B
+18.0% YoY
|
| EBITDA |
255.06M
est: 279.82M (-8.8%)
|
233.42M
est: 453.03M (-48.5%)
|
793.60M
est: 543.63M (+46.0%)
|
1.46B
est: 1.55B (-5.7%)
|
2.27B
est: 2.11B (+8.0%)
|
2.84B
est: 2.62B (+8.3%)
|
2.51B
est: 3.04B (-17.5%)
|
2.32B
est: 2.31B (+0.1%)
|
2.07B
est: 2.97B (-30.2%)
|
3.51B
est: 3.89B (-9.6%)
|
4.74B
est: 3.61B (+31.4%)
|
4.66B
4.61B – 4.70B
+29.0% YoY
|
5.74B
5.74B – 5.74B
+23.2% YoY
|
7.51B
7.51B – 7.51B
+30.9% YoY
|
7.80B
7.80B – 7.80B
+3.8% YoY
|
9.20B
9.20B – 9.20B
+18.0% YoY
|
| EBIT |
232.90M
est: 177.89M (+30.9%)
|
203.48M
est: 288.01M (-29.3%)
|
525.34M
est: 345.61M (+52.0%)
|
1.03B
est: 985.33M (+4.4%)
|
1.81B
est: 1.34B (+34.9%)
|
2.27B
est: 1.67B (+36.2%)
|
1.80B
est: 1.93B (-7.0%)
|
1.57B
est: 1.47B (+6.7%)
|
988.56M
est: 1.89B (-47.7%)
|
2.28B
est: 2.47B (-7.8%)
|
3.42B
est: 2.61B (+31.2%)
|
3.37B
3.33B – 3.40B
+29.0% YoY
|
4.15B
4.15B – 4.15B
+23.2% YoY
|
5.43B
5.43B – 5.43B
+30.9% YoY
|
5.64B
5.64B – 5.64B
+3.8% YoY
|
6.65B
6.65B – 6.65B
+18.0% YoY
|
| Net Income |
136.86M
est: 366.29M (-62.6%)
|
105.99M
est: 671.52M (-84.2%)
|
271.24M
est: 806.89M (-66.4%)
|
533.52M
est: 278.70M (+91.4%)
|
942.44M
est: 478.03M (+97.2%)
|
1.46B
est: 1.08B (+34.7%)
|
1.17B
est: 1.18B (-1.2%)
|
973.80M
est: 1.56B (-37.5%)
|
222.15M
est: 1.79B (-87.6%)
|
949.07M
est: 3.04B (-68.8%)
|
1.87B
est: 2.58B (-27.6%)
|
3.19B
3.07B – 3.30B
+23.4% YoY
|
4.26B
4.19B – 4.34B
+33.8% YoY
|
5.84B
5.82B – 5.87B
+37.1% YoY
|
4.48B
4.48B – 4.48B
-23.4% YoY
|
5.71B
5.71B – 5.71B
+27.7% YoY
|
| SGA |
74.98M
est: 84.51M (-11.3%)
|
78.01M
est: 136.82M (-43.0%)
|
359.37M
est: 164.19M (+118.9%)
|
579.02M
est: 468.09M (+23.7%)
|
716.96M
est: 636.02M (+12.7%)
|
652.34M
est: 790.98M (-17.5%)
|
700.30M
est: 917.54M (-23.7%)
|
766.85M
est: 698.49M (+9.8%)
|
796.88M
est: 897.70M (-11.2%)
|
727.36M
est: 1.17B (-38.0%)
|
865.11M
est: 1.22B (-28.8%)
|
1.57B
1.55B – 1.58B
+29.0% YoY
|
1.93B
1.93B – 1.93B
+23.2% YoY
|
2.53B
2.53B – 2.53B
+30.9% YoY
|
2.62B
2.62B – 2.62B
+3.8% YoY
|
3.10B
3.10B – 3.10B
+18.0% YoY
|
| EPS |
9.92
est: 9.38 (+5.8%)
|
7.68
est: 17.19 (-55.3%)
|
8.86
est: 20.66 (-57.1%)
|
13.66
est: 7.13 (+91.5%)
|
24.13
est: 12.24 (+97.2%)
|
37.38
est: 27.74 (+34.7%)
|
29.93
est: 30.30 (-1.2%)
|
24.93
est: 39.90 (-37.5%)
|
5.45
est: 45.70 (-88.1%)
|
24.30
est: 77.80 (-68.8%)
|
47.87
est: 66.10 (-27.6%)
|
81.55
78.69 – 84.41
+23.4% YoY
|
109.15
107.15 – 111.15
+33.8% YoY
|
149.60
148.97 – 150.23
+37.1% YoY
|
114.60
114.60 – 114.60
-23.4% YoY
|
146.30
146.30 – 146.30
+27.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 217.2K | 0.65% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mahesh Purshottambhai Babani | MD & Chairman | 42M | male |
| Bhaktavatsala Rao Doppalapudi | Executive Director | 2M | male |
| Rajan | President | — | male |
| Ramesh Vishanlal Kathuria | Group Company Secretary & Head Legal | — | male |
| Sanjeev Gajanan Patil | Executive Vice President of Strategy and Biotechnology | — | male |
| Narayan S. Iyer | Chief Financial Officer | — | male |
| Ashwini Saumil Shah | Company Secretary & Compliance Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRIVISCL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
